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 Abstract: 
Patients with primary biliary cholangitis (PBC) can be stratified into low and high-risk groups 
based on their response to treatment. Newly-published guidelines from the British Society 
of gastroenterology suggest low-risk patients can be managed substantially in primary care.  
This represents a shift from existing practice and makes assumptions about service capacity 
and the willingness of both patients and health care practitioners (HCPs) to make this 
change.   
The aim of this paper is to identify possible barriers to the implementation of these new 
care pathways through review of the PBC-specific literature and by identifying the 
experiences of patients and HCPs managing a different condition with comparable patients 
and disease characteristics.   
 
Searches of MEDLINE, CINAHL and EMBASE were undertaken. Within the existing PBC 
literature there is little data surrounding stakeholder perspectives on place of care. Review 
of the breast cancer literature highlights a number of barriers to change including primary 
care practitioner knowledge and work load, communication between healthcare settings, 
and the significance of the established doctor-patient relationship. Further research is 
needed to establish the extent to which these barriers may surface when changing PBC care 
pathways, and the actions required to overcome them.  
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 INTRODUCTION 
 
Primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, is a chronic 
autoimmune liver disease. The incidence of PBC in the UK is 32.2 per 100,000 (1), with 
approximately 20,000 people presently affected. Incidence is higher in females compared to 
males (10:1) and in the 5th and 6th decade of life such that a woman over 40 years of age has 
a 1/1000 chance of having this condition (2). Whilst early natural history studies suggested 
that life expectancy from time of diagnosis was less than 10 years (3), this is no longer true. 
Increasing understanding of the pathophysiology of the disease, along with the ability to 
diagnose PBC earlier in its course, and the widespread use of ursodeoxycholic acid (UDCA) 
has led to the recognition that, for many patients, PBC is a chronic disease but not life 
limiting. The name change from “primary biliary cirrhosis” to “primary biliary cholangitis” 
was adopted into use by clinicians, researchers and patients in 2015 to reflect the emerging 
evidence that only a minority of patients go on to develop cirrhosis and end-stage liver 
failure.  
 
Patients with PBC can be categorised or “stratified” into two groups (responders or non-
responders) based on whether or not there is an improvement in biochemical parameters 
following 12 months of treatment with UDCA. Those who respond to treatment with UDCA 
(between 60-70% of all patients) do not go on to develop progressive disease and have a 
transplant free survival similar to the general population (4-7). Up until a few years ago, in 
the absence of second line treatment, those who failed to respond to UDCA were at risk of  
progression to end stage liver disease and liver transplantation, with younger patients and 
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males with PBC over-represented in this group (8). However, following recent positive 
outcomes in trials, Obeticholic acid (OCA), a Farsenoid X receptor agonist has been 
approved by the National Institute for Health and Care Excellence (NICE) for the treatment 
of patients who have had an inadequate response to treatment with UDCA or were unable 
to tolerate UDCA (9). However, despite the availability of effective treatment, there is no 
cure for the disease and even for those who respond, life-long treatment with UDCA is still 
required and patients will requirement regular follow up.  
 
Reflecting both the increased understanding of the natural history of PBC and the 
availability of second line therapy, recently published guidelines from the British Society of 
Gastroenterology (10) highlight the importance of formal risk stratification for all patients at 
one year post-diagnosis with management of treatment non-response or high risk patients 
necessitating discussion with specialist services for consideration of OCA or clinical trials. For 
those with low-risk disease, whilst long-term treatment and follow-up are required, it has 
been suggested that this does not necessarily need to take place in a hospital based setting 
and there is the opportunity for an increased role for primary care services in the long-term 
care of these patients. These recommendations are echoed in the recent guidelines from 
the European Association for the Study of Liver Disease (11). 
 
New models of care for management of chronic liver disease as a whole are essential and 
timely. In contrast to other countries in Western Europe, rates of liver disease are increasing 
in the UK; over 600,000 people are known to have liver disease with 10% of these having 
cirrhosis and liver disease mortality has increased by 400% over the last 40 years (12). The 
Lancet Commission on Liver Disease has highlighted the numerous challenges currently 
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faced by the NHS and by patients including inequalities in service provision (the so-called 
“postcode lottery”). The Commission’s recommendations included the need to improve 
access to specialist care and services for those most in need as well as increasing 
involvement from primary care and community services (12).  
 
However, changing patterns of established care requires “buy in” from all users of the 
pathways: patients, stakeholders, and HCPs in primary, secondary and tertiary settings. This 
requires an appreciation of the various user’s perspectives of current care, of the possible 
impacts any changes will have on them as new pathways are introduced, and in turn the 
identification of potential barriers to change and the facilitators required for these to be 
overcome. This paper seeks to identify what is already known about these factors in the 
currently available PBC literature.  In addition, we also review the existing literature around 
patient and HCP perspectives on follow up in a comparable condition where recent changes 
in management parallel the proposed evolution of PBC in order to gain insights that may be 
relevant to reforms in PBC care.  
 
METHODS 
 
Review of the PBC Literature 
A scoping review was chosen with the goal of establishing the type and breadth of literature 
available (13). The potential remained to perform a systematic review if the scoping study 
revealed a large body of relevant literature. Using the framework set out by Arksey and 
O’Malley (14),  the following stages were undertaken: 1) identification of the research 
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question, 2) identification of relevant studies, 3) selection of studies, 4) charting of the data 
5) collation, summarising and reporting of results.  
 
The research question was divided into two parts: 1) what is the breadth and type of 
literature available looking at the perspectives of patients and clinicians on all aspects of 
PBC and its management? 2) is there existing data looking specifically at how patients and 
clinicians view the role of primary care in the management of PBC?  
 
A search of three electronic databases: MEDLINE, CINAHL and EMBASE was carried out. A 
schematic of the study selection process is shown in Figure 1. The following search terms 
were used: Primary biliary cirrhosis OR primary biliary cholangitis AND quality OR 
experience OR perception* OR perspective* OR attitude* OR expectation* OR understand* 
OR view*. Eleven hundred and fifty-one distinct citations were identified by the initial 
database searches with 24 included in the final analysis. In order to establish whether there 
were any additional resources available but not captured by the initial electronic database 
searches, a review of all the reference lists from the 24 texts was undertaken; this yielded 
one further article. A search of the grey literature using Open Grey 
(http://www.opengrey.eu) using the search terms “primary biliary cirrhosis” and “primary 
biliary cholangitis” returned 18 and 5 citations respectively. None were relevant to the 
research question. The key characteristics and emerging research themes of the 25 studies 
are summarised in Table 1.  
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Table 1: Summary of research themes in PBC addressing patient and physician perspectives on disease 
 
 
Authorship Publication 
date  
Location  Methodology  Population (size 
of sample with 
PBC) 
Research question 
Blackburn et al 
(15) 
2007 UK Quantitative  Patients (n=24) Are patients with fatigue more psychologically impaired 
than those without fatigue and is there a role for CBT? 
Dyson et al (16) 2016 UK Quantitative  Patients (n=2055) Impact of age at presentation on quality of life and the 
role of symptomatology 
Fahey (17) 1999 UK Literature 
review 
Patients  Experience of women living with PBC and how 
understanding this may improve nursing care  
Gross et al (18) 1999 USA Quantitative  Patients post liver 
transplant  
(n=157, 42% PBC) 
 
Quality of life post-transplant 
Comparison between PBC and PSC patients  
Relationship between quality of life and clinical factors  
 8 
Hale et al (19) 2012 UK Patient 
narrative  
Patients (n=1) 
 
Experience of living with fatigue 
Huet et al (20) 2000 Canada Quantitative  Patients (n=116) 
Healthy controls  
 
Validation of the fatigue impact score in a large patient 
cohort 
Link between fatigue and mental health status 
Relationship between psychosocial and physical factors 
Ismond et al (21) 
 
*conference 
abstract only 
2018 Canada Mixed methods 
(quantitative 
with post hoc 
qualitative 
analysis 
Patients 
(n=119) 
Experience of living with PBC 
Impact on daily life and relationships 
Jorgenson (22) 2006 USA Qualitative Patients (n=8) Experience of living with fatigue 
 
Lasker et al (23) 2005 USA Qualitative  Patients (n=275) Why do patients use internet resources? 
Does disease stage affect disease experience? 
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What are the similarities between issues experiences by 
patients with PBC and those with other chronic disease? 
 
Lasker et al (24) 2010 USA Quantitative  Patients on 
waiting list or 
post-transplant 
(n=100) 
Uncertainty and how it relates to quality of life scores 
 
Mells et al (25) 2013 UK Quantitative  Patients (n=2402) Quality of life scores and the role of fatigue, depression, 
sleep, social and cognitive function 
Miura et al (26) 
*conference 
abstract only 
2016 Japan Quantitative Patients (n=217) Symptom profile and impact on quality of life 
Montali et al (27) 2011 Italy Qualitative  Patients (n=23) Illness experience of women with PBC, sick role and 
relationship with others 
Navasa et al (28) 1996 Spain Quantitative  Patients post liver 
transplant (n=29) 
Quality of life scores, complications and use of medical 
services post-transplant  
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Pearce et al (29) 2011 UK Qualitative  Patients (n=28+) Experience of receiving a diagnosis of PBC. 
Use of this information to develop resources for patients 
at diagnosis 
Poupon et al (30) 2004 France Quantitative  Patients (n=276) Comparison of quality of life scores amongst patients 
compared to healthy controls. 
Relationship between clinical parameters and quality of 
life  
Impact of UDCA use on quality of life  
Raszeja-
Wyszomirska et 
al (31) 
2015 Poland Quantitative Patients (n=205) 
Healthy controls 
Comparison of quality of life domains between patients 
and controls 
Impact of patient and disease related factors on quality 
of life 
Rishe et al (32) 2008 USA Quantitative  Patients (n=238) 
 
Experience of living with itch 
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Saich et al (33) 
 
*conference 
abstract only 
2015 USA Quantitative  Patients (n=214) 
and physicians 
(n=322) 
 
Comparison of patient perceptions of care vs physician 
perspectives. 
Selmi et al  (34) 2007 USA Quantitative  Patients (n=1032) Comparison of activity scores, symptoms and social life 
scores between patients and healthy controls 
Sogolow et al 
(35) 
2010 USA Mixed methods Patients (n=100) Experience of stigma associated with diagnosis. 
Why do some women experience more stigma than 
others? 
What impact does stigma have on quality of life? 
Stanca et al  (36) 2005 USA Quantitative Patients (n=70) Impact of fatigue on quality of life 
Untas et al (37) 
 
2015 France  Quantitative  Patients (n=130) 
 
Quality of life perception amongst women with PBC 
compared to a group of women with diabetes. 
Yagi et al  (38) 
*conference 
2016 Japan Quantitative Patients (n=180) Comparison between patient and physician reported 
symptoms  
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abstract only 
Wong et al  (39) 2008 China Quantitative  Patients (n=44) Comparison of symptoms scores, quality of life scores 
and depression scores between patients with PBC and 
two control groups (hypertension and chronic hepatitis B)  
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Figure 1: Study selection process for PBC 
 
Choosing a comparable condition 
 
A number of factors were deemed to be of relevance when selecting a comparable 
condition including the demographics of the patient population, availability of clear 
stratification parameters, and the need for ongoing but minimal input long-term follow up 
for low-risk groups. Possible conditions considered included other forms of liver disease, 
other chronic diseases (including autoimmune and non-autoimmune) and malignancies. 
Breast cancer satisfied the criteria (see table 2); it is mainly a disease of older females, 
patients are stratified after primary treatment into those who have achieved remission and 
those who have not responded, and even where remission has been achieved, there 
continues to be a need for a form of life-long input for responders that does not necessarily 
require specialist input (40). A number of other parallels are also evident, including the 
ongoing psychological morbidity, and symptoms that may persist despite remission being 
achieved. In addition, issues around how best to follow up patients who have undergone 
curative treatment remain a source of debate (41). NICE guidelines on breast cancer from 
2002 stated that all patients should be followed up for a minimum of 3 years (although they 
did not state how frequently patients should be seen) before care could be transferred back 
to primary care (42). A systematic review of the breast cancer literature in 2007 (43) 
identified seven randomised controlled trials (RCTs) which compared different forms of 
follow-up care both in terms of frequency of review and appropriate healthcare 
professional. Overall, they found no difference in recurrence rates, survival or quality of life. 
The updated NICE guidelines in 2009 (44) reflect the existing research and recommend 
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patients decide how they would like to be followed up after primary treatment is completed 
with options including primary care, secondary care or shared care .  
 
 
Table 2: Comparison of primary biliary cholangitis and breast cancer  
 
 PBC Breast cancer 
Gender  F:M 9:1 (2) F:M 99:1 (40) 
Age  Most common in 5th 
and 6th decade (2) 
50% over 65 (40) 
Prognosis  70% response rate (6) >70% 5 year survival (40) 
Long term treatment required Yes, UDCA Some cases – hormonal 
treatment 
Long term symptoms Itch and fatigue Lymphoedema  
 
 
Review of the breast cancer literature 
 
The second scoping exercise again followed the Arksey and O’Malley structure (14). As the 
topic of long-term follow-up in breast cancer survivorship has been widely studied, the goal 
of this review was to 1) gain an overview of the commonly occurring themes in this 
literature and 2) identify barriers to follow up in primary care which may have potential 
relevance in PBC. An electronic database search was undertaken using the same three 
databases. A schematic of the sample selection process is shown in Figure 2. The following 
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search terms were used: breast cancer OR breast carcinoma OR breast neoplasm AND 
perspective* OR opinion* OR view* OR attitude* OR experience* or perception* AND 
discharge OR “follow up” OR “primary care” OR “secondary care” OR hospital* OR special* 
OR “general practice*. A date limit was set to cover 1996-2016 in order to capture data 
relevant to recent changes in breast cancer follow up strategies between the 2002 and 2009 
NICE guidelines and studies undertaken following this change in practice. Review of the 
reference lists from relevant articles did not identify any further relevant citations within 
the specified date range. For each study the following data was extracted: authorship, 
publication date, location, population type, sample size, and barriers to primary care follow 
up.   
 
Figure 2:  Study selection process for breast cancer  
 
RESULTS 
 
PBC literature 
Twenty-five studies identified from the PBC literature were included in the final analysis 
(Table 1). Seventeen quantitative studies were identified (15, 16, 18, 20, 24-26, 28, 30-34, 
36-39), 4 qualitative (22, 23, 27, 29), 2 mixed methods study (21, 35), 1 literature review 
(17) and 1 patient narrative (19) . Of these studies, 24 focussed on the patient perspective 
only, with one looking at both patient and physician perspectives (33). The majority of the 
studies focused on symptoms and quality of life. Of those that took a qualitative or mixed 
approach, one study looked specifically at the impact of fatigue (22), one at the experience 
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of receiving a diagnosis (29) and the other at stigma associated with PBC (35). Two studies 
explored the experience of living with PBC (21, 27).  
 
Whilst no studies directly addressed issues surrounding follow-up care and the role of 
primary, secondary and tertiary care, there were a number of emerging themes that are 
likely to be of relevance when looking at the impact of changes in the structure of care. 
Montali (27)  identified the theme of “delegitimisation” and how, when patients look well 
(as is often the case in PBC), the impact of their disease is minimised by familial and social 
contacts. Discharge from specialist care to the primary care setting may further impact 
these perceptions both for the patient and their social contacts. The significance of the 
disease may be perceived as lesser when care is transferred to practitioners who may be 
seen as being less ‘specialist’ or ‘expert’ (19, 29). In addition, the stigma experienced by 
patients may also be influenced by new changes in care structure. A study looking at posts 
on an internet forum for patients with PBC revealed that a number of posts were related to 
stigma (23) and when directly asked many patients reported that they felt a degree of 
stigma associated with their disease (35). This stigma seemed to stem not specifically from 
the diagnosis of PBC itself but with the associations between liver disease and cirrhosis with 
drug and alcohol. Of note, this stigma was not just related to the perception of lay people 
but also to non-specialist HCPs.  
 
Breast cancer literature 
From the breast cancer literature, 14 papers were included in the final analysis (Table 3). 
Quantitative methods were used in 8 of the studies (45-52), 5 used qualitative methods (53-
58) and 1 mixed methods study (58) was identified. Nine studies looked at the views of the 
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patient population (46-48, 50, 53-57), 6 included primary care clinicians (46, 48, 49, 55, 57, 
58) and 5 included specialists (comprising surgeons, oncologists and nurses) (45, 51, 52, 55, 
56) 
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Table 3: Summary of themes identified in breast cancer literature 
 
 
Authorship Publication 
date 
 Location  Methodology Population  
(size of 
sample) 
Findings/themes identified 
Adewuyi-Dalton 
et al (53) 
1998 UK Qualitative – face to 
face one on one 
interviews  
Patients 
(n=109) 
GPs - overworked; lack specialist knowledge; specialist 
care less important over time as concern about recurrence 
lessens. 
 
Brennan et al 
(51) 
2010 Australia Quantitative – 
questionnaire 
Secondary 
care (n=217) 
GPs need more training to follow up patients 
Brennan et al 
(54) 
2011 Australia Qualitative  - 
telephone interviews  
Patients 
(n=20) 
Advantages GP care: convenience, reduced travel 
involved, take pressure off specialists 
Disadvantages of GP care: poor communication between 
specialist and GP, GPs lack of knowledge, established 
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relationship with specialist during treatment 
Dawes et al (58) 2015 USA Mixed methods - 
questionnaire and 
focus group 
Primary care  
(Survey n=59 
Focus group 
n=36+) 
Favoured specialists to provide follow up care 
Lack of knowledge especially endocrine treatment 
Donelly et al 
(45) 
2007 UK Quantitative – 
questionnaire 
Secondary 
care (n=256) 
Advantages of GP care: reduced clinic workload. 
Disadvantages: lack of training, loss of outcome data 
Kantsiper et al 
(55) 
2009 USA Qualitative - focus 
group  
Patients 
(n=21) 
Primary care 
(n=15) 
Secondary 
care (n= 160 
Specialists are experts and GPs role is in referral not 
management. feelings of abandonment on discharge 
Fear of missing recurrence and medicolegal implications, 
not able to keep up to date with information, poor 
communication from specialists 
Better at detecting recurrence and managing side effects 
than GPs, like following up survivors (positive experience), 
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establish bond with patient 
 
Kerrigan et al 
(46) 
2014 Ireland Quantitative Patients 
(n=87) 
 
Primary care ( 
n= 53) 
Supportive of GP care: able to explain breast cancer, able 
to perform examination, easy links to specialist if needed 
Increased workload and costs, concern regarding 
medicolegal aspects of care 
 
Kwast et al (56) 2013 Netherlands Qualitative – face to 
face interviews 
Patients 
(n=23) 
Clinicians 
(n=18) 
GP -  role in psychosocial aspects of care; lacks specialist 
knowledge; too busy 
GP care cheaper; lack specialist knowledge 
Luker et al (57) 2000 UK Qualitative – face to 
face/telephone 
interviews 
Patients 
(n=67)  
 
Primary care 
GP - lacks knowledge; delay in diagnosis associated with 
decreased confidence in follow up 
Difficult to keep up to date with new information, 
prognostication challenging 
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(n=31) 
Mao et al (50) 2009 USA Quantitative  Patients 
(n=300) 
Holistic care through GP; psychosocial aspects of 
management; variable breast cancer specific knowledge 
Mayer et al (47) 2012 Canada Quantitative Patients 
(n=218) 
Specialist visit reduces anxiety and improves survival 
compared with primary care 
Roorda et al 
(49) 
2013 Netherlands Quantitative - 
questionnaires 
Primary care  
(n=502) 
40% of GPs happy to provide exclusive care after 5 years; 
barriers – patient preference, lack of knowledge, workload 
improving GP care 
improving GP care - active discharge from specialist care, 
written information, education, easy access back to 
specialist care if required. 
Smith et al  (48) 2015 Canada Quantitative  Patients 
(n=1065) 
Primary care 
(n=587) 
Confident in GPs ability to screen for recurrence, less 
confident in GPs managing osteoporosis, hormonal 
treatment 
Confident in screening for recurrence, lower confidence in 
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lymphoedema, family counselling, psychosocial aspects 
 
Van Hezewijk et 
al (52) 
2011 Netherlands Quantitative – 
questionnaire 
Secondary 
care (n=130) 
GPs should play a minor role in follow up. Reasons not 
specified 
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Barriers to primary care follow up identified included lack of knowledge amongst primary 
care physicians which was a recurrent theme amongst patients (50, 53, 54, 57), specialists 
(45, 51, 56) and primary care physicians themselves (49, 57, 58). Allied to this concern was a 
fear that recurrence could be missed which was expressed by both primary care and 
specialist care (55) with some primary care clinicians expressly mentioning medicolegal 
concerns (46, 55). There was an association between cases where patients had experienced 
delays at the time of initial diagnosis and reduced confidence in their primary care 
practitioners ability to provide adequate follow up (57). When asked to rate their survival 
outcomes in different healthcare settings, patients felt that their chance of survival long 
term was higher if they were followed up by a specialist (47).  
 
In terms of practical aspects of care, both patients and doctors felt that primary care 
clinicians are already overworked (46, 49, 53), that communication between primary care 
and specialists was poor (54, 55) and this may impact on care. Specialists highlighted that 
they would lose long-term outcome data if they did not follow up patients themselves (45). 
They also described the relationship that forms with patients over time which was echoed 
by patients who described forming a bond with their specialists and feelings of 
abandonment when discharged (54, 55). The specialists reported the positive reinforcement 
they received from following up patients in remission rather than just seeing patients with 
complications and more advanced/untreatable disease (55).  
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DISCUSSION 
 
This scoping exercise identified the paucity of available literature exploring patient and HCP 
perspectives on the follow up and management of PBC and a lack of any data around the 
role of primary care in the long term management of patients with low-risk PBC. However, 
studies reporting stakeholder perspectives on changes to the delivery of breast cancer 
follow-up care have shown that not all patients or practitioners are comfortable with 
management being located substantially in the primary care setting. A series of themes 
emerged which have relevance to proposed care pathway changes including the knowledge 
base and workload of primary care, communication between care settings and the 
importance of the doctor-patient relationship. Within the data available specifically for PBC, 
the impact of delegitimisation and stigmatisation felt by PBC patients is likely to be of 
relevance when developing new strategies for follow up care.   
 
This scoping review has identified a gap in the literature around patient and HCP 
perspectives on management in primary care and the need for further study in this area to 
look specifically at the potential concerns of users of this pathway and whether or not the 
themes identified in this scoping review are relevant, if there are additional barriers or 
facilitators not identified here and, if so, how they can be overcome.  
 
As is common with the use of a scoping review rather than a systematic review, there was a 
focus on identifying the breadth of literature available rather than looking at the available 
studies in depth and the quality of the studies identified was not assessed. However, the 
identification that there is little relevant literature in this field meant that this was less 
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important. We aimed to conduct a comprehensive search of the literature, using a multiple 
database strategy. However, it is possible that some relevant articles were missed. The lack 
of identification of additional relevant studies from reference lists of the chosen papers 
would support the belief that the search identified the relevant data in the field. Finally, it is 
not possible to know whether, and to what extent, any of the conditions considered by the 
authors for the second stage of the scoping study (including other forms of autoimmune 
disease, other forms of chronic liver disease and breast cancer) truly act as comparators to 
PBC. Whilst breast cancer was chosen as a comparator condition due to its similarities to 
PBC in terms of demographics of the patient population, this decision makes the assumption 
about the overall importance of patient demographics in determining its healthcare related 
behaviours. In addition, there are likely to be fundamental differences in comparing a 
malignant and non-malignant condition that will impact on how patients and clinicians view 
their future care needs. Finally, PBC as a rare disease is likely to pose different challenges to 
breast cancer which is now relatively common.  
 
CONCLUSION 
 
The recent guidelines from both the UK and European Societies propose a shift towards 
individualised care for patients with PBC. Whilst individualised care is not explicitly defined, 
one potential consequence that is discussed in the British Guidelines is the discharge of 
patients deemed “low risk” from hospital care to follow up in primary care. The feasibility of 
this strategy is unclear and as such, the purpose of this scoping review was to identify the 
breadth and depth of the data already available about patient and clinician perspectives on 
management in primary care in order to identify facilitators and barriers to implementing 
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this in practice. This review however highlighted that there is in fact a lack of data and that 
in order to be able to definitively answer the question of feasibility within PBC, further study 
may be required.  
 
In developing a stratified approach to the care of the patient with PBC it will be essential to 
frame changes in care around high quality research.  Underpinning this are opportunities to 
change practice by first of all an emphasis on education.  This should address specific 
education for patients with PBC, and for primary care physicians, a broader education effort 
on the management of chronic liver diseases. With such an approach there would then be a 
greater opportunity to perhaps implement further change though targeted education, and 
use of smart technology/Apps to aid individualise risk assessment and changes to care 
pathways.  Any approaches to change would require sensitive implementation adapted to 
local resources: for example where large group practices and primary networks exist in 
primary care, opportunities to use a few embedded primary care liver champions may be 
effective, whereas in rural areas, IT/nurse supported change to care for GPs may be better. 
 
Across the various models of health care delivery, it will be essential to evaluate feasibility 
of stratified care for patients with PBC in many different settings and health care models.  
Solutions for urban areas may, for example, be distinct to those for rural environments, and 
obstacles to implementation may include economic and personnel issues.  Nevertheless, 
there exists the opportunity to be innovative in service design and then to evaluate the 
impact of any service change. 
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We believe the similarities between the patient, disease and management characteristics of 
post-surgery breast cancer and low-risk PBC patients to be such that it is reasonable to 
anticipate comparable barriers will emerge to the implementation of the new management 
guidelines for PBC. Dedicated research involving patients and clinicians is still required to 
confirm that barriers to change exist, to identify what these barriers are, and to plan 
strategies for intervention in this group of patients and clinicians. This information will be 
relevant not only to the possible future implementation of stratified care models in the PBC 
population but will also be applicable to other rare chronic diseases including, but not 
exclusive to, liver disease.  
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